The Quinapril Ischemic Event Trial (QUIET): Evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function

American Journal of Cardiology

Volumn 87, Issue 9, 2001, Pages 1058-1063

  Pitt, Bertram ^a   O'Neill, Blair ^b   Feldman, Robert ^c   Ferrari, Roberto ^d   Schwartz, Leonard ^e   Mudra, Harald ^f   Bass, Theodore ^g   Pepine, Carl ^h   Texter, Michele ⁱ   Haber, Harry ⁱ   Uprichard, Andrew ⁱ   Cashin Hemphill, Linda ^j   Lees, Robert S ^j  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^c Mediquest Research   (United States)

^d UNIVERSITY OF BRESCIA   (Italy)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g Kls Martin   (United States)

^h UNIVERSITY OF FLORIDA   (United States)

ⁱ PFIZER INC   (United States)

^j Boston Heart Foundation   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; NITRIC ACID DERIVATIVE; PLACEBO; QUINAPRIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; COUGHING; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; ANGIOPLASTY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; ISOQUINOLINES; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 0035328174     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01461-8     Document Type: Article

References (29)

1. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet
2. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) study
3. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)
4. Effects of captopril on atherosclerosis in cynomolgus monkeys
5. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit
6. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-?B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis
7. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
8. The effect of captopril on mortality and morbidity in patients with left ventricular dysfunction following myocardial infarction. Results of the survival and ventricular enlargement trial
9. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
10. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
11. Can ACE inhibition alter the course of coronary heart disease? Rationale and protocol for QUIET
12. The QUinipril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention
13. Baseline clinical and angiographic data in the Quinapril Ischemic Event Trial (QUIET)
14. Discrete sequential boundaries for clinical trials
15. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: No answer yet
16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvistatin survival study (4S)
17. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
18. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
19. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin
20. The pathogenesis of coronary artery disease and the acute coronary syndromes
21. Prognostic significance of progression of coronary atherosclerosis
22. Changes in sequential coronary arteriograms and subsequent coronary events: Program On the Surgical Control of the Hyperlipidemias (POSCH) group
23. Progression of coronary artery disease predicts clinical coronary events: Long-term follow-up from the cholesterol lowering atherosclerosis study
24. Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects?
25. Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril in rats
26. Differentiation of angiotensin converting enzyme inhibitors (ACE) by their selective inhibition of ACE in physiologically important target organs
27. Vascular affinity of trandolapril
28. Beneficial effects of quinapril on ischemia in coronary bypass surgery patients - One year follow-up of the QUO VADIS study
29. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function